Hologic Inc. (NASDAQ:HOLX) has earned an average recommendation of “Buy” from the seventeen research firms that are covering the company. Six research analysts have rated the stock with a hold recommendation, ten have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $43.17.

Several research firms have commented on HOLX. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a report on Thursday, July 28th. Leerink Swann reissued an “outperform” rating and issued a $46.00 target price on shares of Hologic in a research report on Monday, October 3rd. Barclays PLC reissued a “buy” rating and issued a $45.00 target price on shares of Hologic in a research report on Thursday, November 3rd. Zacks Investment Research cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Finally, Evercore ISI raised shares of Hologic from a “hold” rating to a “buy” rating and boosted their target price for the company from $38.00 to $42.00 in a research report on Thursday, July 28th.

Shares of Hologic (NASDAQ:HOLX) opened at 36.74 on Wednesday. Hologic has a 52-week low of $31.84 and a 52-week high of $41.66. The firm has a market cap of $10.20 billion, a PE ratio of 31.67 and a beta of 1.13. The firm has a 50-day moving average of $38.05 and a 200 day moving average of $36.58.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, November 2nd. The company reported $0.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.02. Hologic had a net margin of 11.68% and a return on equity of 26.76%. The firm had revenue of $726.80 million for the quarter, compared to the consensus estimate of $721.52 million. During the same period in the previous year, the company earned $0.43 earnings per share. The company’s quarterly revenue was up 3.4% on a year-over-year basis. On average, equities analysts predict that Hologic will post $2.14 earnings per share for the current year.

In other news, VP Karleen Marie Oberton sold 31,470 shares of the company’s stock in a transaction that occurred on Monday, October 10th. The stock was sold at an average price of $40.00, for a total value of $1,258,800.00. Following the completion of the transaction, the vice president now owns 17,005 shares of the company’s stock, valued at $680,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Elaine Ullian sold 18,236 shares of the company’s stock in a transaction that occurred on Monday, October 10th. The shares were sold at an average price of $39.88, for a total value of $727,251.68. Following the completion of the transaction, the director now directly owns 42,898 shares of the company’s stock, valued at approximately $1,710,772.24. The disclosure for this sale can be found here. 0.84% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the stock. UBS Asset Management Americas Inc. increased its stake in Hologic by 1.2% in the first quarter. UBS Asset Management Americas Inc. now owns 637,813 shares of the company’s stock worth $22,006,000 after buying an additional 7,810 shares in the last quarter. Cleararc Capital Inc. purchased a new stake in Hologic during the first quarter worth $213,000. Geode Capital Management LLC increased its stake in Hologic by 54.3% in the first quarter. Geode Capital Management LLC now owns 2,328,326 shares of the company’s stock worth $80,187,000 after buying an additional 819,646 shares in the last quarter. Hancock Holding Co. increased its stake in Hologic by 2.2% in the first quarter. Hancock Holding Co. now owns 46,261 shares of the company’s stock worth $1,596,000 after buying an additional 977 shares in the last quarter. Finally, Kennedy Capital Management Inc. purchased a new stake in Hologic during the first quarter worth $3,592,000. 94.61% of the stock is owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.

5 Day Chart for NASDAQ:HOLX

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.